CK Life Sciences International (Holdings), Inc. (HK:0775)
:0775
Want to see HK:0775 full AI Analyst Report?
Top Page
CK Life Sciences International (Holdings), Inc.
(0775)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$0.69
▼(-17.11% Downside)
Action:ReiteratedDate:04/21/26
The score is primarily weighed down by deteriorating financial performance, including sharp margin compression, deeper losses, and a shift to negative operating and free cash flow alongside elevated leverage. Technical indicators also reflect a weak trend (below key moving averages with negative MACD). Valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Diversified life-sciences business model
CK Life Sciences operates across health products, agriculture solutions and environmental services plus investment activities. This sector diversification spreads revenue risk, enables cross-market opportunities and increases resilience to single-market shocks, supporting steadier fundamentals over months.
Negative Factors
Sharp margin compression and operating losses
Gross margin collapsing from ~30.6% to ~14.5% and the shift to negative EBIT/EBITDA indicate a major deterioration in core profitability. Sustained margin pressure erodes pricing power and operating leverage, making it harder to restore sustainable profits without material revenue or cost-structure changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified life-sciences business model
CK Life Sciences operates across health products, agriculture solutions and environmental services plus investment activities. This sector diversification spreads revenue risk, enables cross-market opportunities and increases resilience to single-market shocks, supporting steadier fundamentals over months.
Read all positive factors
CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.92B
Dividend YieldN/A
Average Volume (3M)7.56M
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth-2.04%
EPS Growth-46.97%
CountryHK
Employees2,033
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding9,611,072,000
10 Day Avg. Volume13,068,694
30 Day Avg. Volume7,559,299
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)2.09
Price to Sales (P/S)1.46
P/FCF Ratio-28.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model
Company Description
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and mark...
How the Company Makes Money
CK Life Sciences makes money primarily through (1) selling products and services from its operating businesses and (2) earning income from investments in life-sciences-related entities. Key revenue streams include: (a) revenue from the health prod...
CK Life Sciences International (Holdings), Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
43
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.41B | 5.52B | 5.32B | 5.28B | 5.40B |
| Gross Profit | 785.38M | 1.69B | 1.64B | 1.63B | 1.63B |
| EBITDA | -49.42M | 337.27M | 624.75M | 469.51M | 449.14M |
| Net Income | -188.45M | -126.55M | 17.25M | 131.96M | 162.80M |
Balance Sheet | |||||
| Total Assets | 11.84B | 10.79B | 11.25B | 11.27B | 11.73B |
| Cash, Cash Equivalents and Short-Term Investments | 603.07M | 571.21M | 676.16M | 704.13M | 902.47M |
| Total Debt | 6.62B | 6.10B | 5.93B | 5.95B | 6.21B |
| Total Liabilities | 7.99B | 7.28B | 7.06B | 7.11B | 7.23B |
| Stockholders Equity | 3.78B | 3.51B | 4.19B | 4.16B | 4.50B |
Cash Flow | |||||
| Free Cash Flow | -277.76M | 157.00M | 222.35M | 146.69M | 206.33M |
| Operating Cash Flow | -32.77M | 353.53M | 514.18M | 363.66M | 423.57M |
| Investing Cash Flow | -362.68M | -96.64M | -67.96M | -22.12M | -257.88M |
| Financing Cash Flow | 428.57M | -341.98M | -477.95M | -515.34M | -220.08M |
CK Life Sciences International (Holdings), Inc. Technical Analysis
Negative
0.83
Price Trends
0.78
Negative
0.81
Negative
0.87
Negative
Market Momentum
-0.01
Negative
46.78
Neutral
55.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Negative. The current price of 0.83 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.78, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.78 is Neutral, neither overbought nor oversold. The STOCH value of 55.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0775.
CK Life Sciences International (Holdings), Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | HK$21.41B | 73.24 | 11.29% | ― | 48.38% | ― | |
54 Neutral | HK$17.48B | -9.33 | -12.74% | ― | 57.92% | -23.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$11.51B | 5.89 | 18.28% | ― | 314.06% | 3050.00% | |
47 Neutral | HK$6.03B | -34.12 | -4.32% | ― | 93.26% | 49.33% | |
41 Neutral | HK$6.92B | -41.82 | -5.07% | ― | -2.04% | -46.97% |
* Healthcare Sector Average
HK:0775
CK Life Sciences International (Holdings), Inc.
0.72
-0.21
-22.58%
HK:1477
Ocumension Therapeutics
7.40
1.96
36.03%
HK:1672
Ascletis Pharma, Inc.
16.47
9.92
151.45%
HK:2142
HBM Holdings Ltd.
13.01
4.20
47.67%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
52.40
38.50
276.98%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.84
-3.78
-35.59%
CK Life Sciences International (Holdings), Inc. Corporate Events
CK Life Sciences Sets 2026 AGM, Seeks Share Issue Mandate and Fee Changes
Apr 17, 2026
CK Life Sciences International (Holdings) Inc. has called its 2026 annual general meeting as a hybrid event to be held in Hong Kong and online on 21 May 2026, with a contingency date set for 27 May in case of severe weather. Shareholders will rece...
CK Life Sciences Unit Showcases Preclinical Cancer Vaccine Advances at AACR 2026
Mar 31, 2026
CK Life Sciences’ subsidiary Sequencio Therapeutics will present preclinical data from its cancer vaccine pipeline at the AACR Annual Meeting 2026 in San Diego, marking its first major scientific showcase. The five abstracts cover investigat...
CK Life Sciences Deepens R&D Pivot as 2025 Loss Widens on Investment and One-Offs
Mar 17, 2026
CK Life Sciences reported a loss attributable to shareholders of HK$186.8 million for 2025, driven by higher RD spending and non-cash extraordinary items, despite stronger profits from its commercial businesses. Excluding one-off effects, net prof...
CK Life Sciences Launches Sequencio to Drive Cancer Vaccine Portfolio
Mar 10, 2026
CK Life Sciences International (Holdings) Inc. has formed Sequencio Therapeutics Company Limited as a wholly owned subsidiary to consolidate and drive its therapeutic cancer vaccine research and development efforts. The move underscores the group&...
CK Life Sciences Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 5, 2026
CK Life Sciences International (Holdings) Inc. has scheduled a board meeting in Hong Kong on 17 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the declaration of a fi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.